Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, soared 5.37% in pre-market trading on November 6, 2024. The rally came on the heels of the company's robust third-quarter 2024 financial results, which exceeded analysts' expectations.
CareDx reported a 23% year-over-year increase in revenue to $82.9 million, surpassing analysts' estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earnings per share loss of $0.14 was better than the expected loss of $0.43.
Looking ahead, CareDx forecasts revenue growth of 12% per annum on average over the next three years. While this growth projection lags behind the 21% forecast for the broader US biotechnology industry, it nevertheless reflects the company's continued expansion and potential for further profitability improvements.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。